Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › REBUILDING-1 (RAY1225, NCT06254261)

REBUILDING-1 (RAY1225, NCT06254261)

RAY1225 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
RAY1225
Population
obesity
Phase
2
Participants
172
Duration
24 weeks
Registry
NCT06254261

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
3 mg Q2Wobesity china24172——−10.1 % vs −3.5 %
estimand not specified
———————press release
6 mg Q2Wobesity china24172——−13.0 % vs −3.5 %
estimand not specified
———————press release
9 mg Q2Wobesity china24172——−15.1 % vs −3.5 %
estimand not specified
———————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (3)
  • 3 mg Q2W · weight_unsp · HKEX filing
    治疗 24 周体重呈剂量依赖性下降,体重较基线相对变化的最小二乘均数分别为-10.05%、-12.98%和-15.05%,安慰剂组为-3.55%
  • 6 mg Q2W · weight_unsp · HKEX filing
    治疗 24 周体重呈剂量依赖性下降,体重较基线相对变化的最小二乘均数分别为-10.05%、-12.98%和-15.05%,安慰剂组为-3.55%
  • 9 mg Q2W · weight_unsp · HKEX filing
    治疗 24 周体重呈剂量依赖性下降,体重较基线相对变化的最小二乘均数分别为-10.05%、-12.98%和-15.05%,安慰剂组为-3.55%

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: REBUILDING-1 (RAY1225, NCT06254261). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/rebuilding-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.